Evidence map›Paper›PMID 38347997›Full record

ArticleCureus2024

Allopurinol-Induced Toxic Epidermal Necrolysis.

Sofia Perdigão, Ana Sofia Alves, Mariana Nunes, Cristiana Sousa, Nelson Barros

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sofia PerdigãoInternal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro (Hospital Center of Trás-os-Montes and Alto Douro), Chaves, PRT.
Ana Sofia AlvesInternal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro (Hospital Center of Trás-os-Montes and Alto Douro), Chaves, PRT.
Mariana NunesInternal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro (Hospital Center of Trás-os-Montes and Alto Douro), Chaves, PRT.
Cristiana SousaInternal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro (Hospital Center of Trás-os-Montes and Alto Douro), Chaves, PRT.
Nelson BarrosIntensive Care Unit, Centro Hospitalar de Trás-os-Montes e Alto Douro (Hospital Center of Trás-os-Montes and Alto Douro), Vila Real, PRT.
Unidade Local de Saúde de Trás-os-Montes e Alto Douro · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic epidermal necrolysis (TEN) is a rare and life-threatening cutaneous disease, frequently triggered by drugs. Allopurinol is one of the most frequent drugs associated with TEN, which implies detachment of a significant amount of the body surface area (BSA) and has a high morbidity and mortality associated with it. We present the case of a 68-year-old female with a recent diagnosis of hyperuricemia who started treatment with allopurinol. A week later, she presented to the emergency department with an extensive maculopapular exanthema with blisters and skin detachment. After the exclusion of other etiologies, the diagnosis of allopurinol-induced TEN was made, with 35% of BSA involvement. Due to the severity of the clinical condition, she was admitted to intensive care and treated with corticoids that had no response. So, she was started on immunoglobulins and transferred to a burn unit. She developed sepsis with multiorgan failure and required supportive treatment. She was discharged after a month, and physical rehabilitation was needed. This clinical case highlights the severity of allopurinol hypersensitivity that may happen and the importance of an accurate diagnosis and treatment for this rare disease.

Indexed as

allopurinolallopurinol hypersensitivitystevens-johnson syndrome (sjs)toxic epidermal necrolysis (ten)toxicity

Identifiers

PMID38347997
PMCPMC10861211
OpenAlexW4390854034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.